Israel
Novamed's expertise lies in the production of high-quality in-vitro diagnostics (IVD) products, with advanced platforms and test kits tailored for point-of-care testing and laboratory use. With a remarkable 25-year legacy of scientific innovation, the company operates an ISO 13485 certified manufacturing facility that distributes its product portfolio globally.
Notably, Novamed's products have received approval from the Israeli health ministry, and several have also obtained CE and FDA approval. It’s worth mentioning that the company is under the umbrella of Simplivia Healthcare Ltd, a provider of high-quality FDA approved medical solutions for drug delivery, safeguarding the wellbeing of healthcare professionals. Simplivia is supported by FIMI Opportunity Fund, recognized as one of the top 5 investment funds globally in terms of performance consistency. The company was founded in 1995 and operates within the Biopharma, Biotechnology, Health Care, Life Sciences, and Manufacturing industries. Although specific headquarter information and the details of the last investment and investors are not available, Novamed's strong market position and its association with Simplivia Healthcare Ltd, backed by FIMI Opportunity Fund, underscore its potential for continued success and growth within the life sciences and in-vitro diagnostics spheres.
